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The transcription factor Nrf2 (nuclear factor-erythroid 2 p45-related factor
2) functions at the interface of cellular redox and intermediary metabolism.
Nrf2 target genes encode antioxidant enzymes, and proteins involved in
xenobiotic detoxification, repair and removal of damaged proteins and
organelles, inflammation, and mitochondrial bioenergetics. The function of
Nrf2 is altered in many neurodegenerative disorders, such as Huntington’s
disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and Friedreich’s
ataxia. Nrf2 activation mitigates multiple pathogenic processes involved in
these neurodegenerative disorders through upregulation of antioxidant
defenses, inhibition of inflammation, improvement of mitochondrial func-
tion, and maintenance of protein homeostasis. Small molecule pharmaco-
logical activators of Nrf2 have shown protective effects in numerous
animal models of neurodegenerative diseases, and in cultures of human
cells expressing mutant proteins. Targeting Nrf2 signaling may provide a
therapeutic option to delay onset, slow progression, and ameliorate symp-
toms of neurodegenerative disorders.
Introduction
The transcription factor Nrf2 (nuclear factor erythroid
2 p45-related factor 2) regulates the expression of
genes involved in cellular protection against damage
by oxidants, electrophiles, and inflammatory agents,
and in the maintenance of mitochondrial function, cel-
lular redox, and protein homeostasis [1]. Nrf2 protein
comprises seven functional domains termed Nrf2-ECH
homology (Neh) 1–7 domains (Fig. 1). Nrf2 binds one
of its major negative regulators, Kelch-like ECH-asso-
ciated protein 1 (Keap1) through its N-terminal Neh2
domain. Neh4 and Neh5 are transactivation domains
that recruit cAMP response element-binding protein
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(CREB)-binding protein (CBP) and/or receptor-asso-
ciated coactivator 3 (RAC3). The Neh7 domain medi-
ates binding to retinoid X receptor alpha (RXRa),
another negative regulator of Nrf2. The Neh6 domain
mediates interaction with a third negative regulator,
b-transducin repeat-containing protein (b-TrCP). Neh1
is responsible for the formation of a heterodimer with
small musculoaponeurotic fibrosarcoma (sMaf) pro-
teins, and mediates binding to antioxidant/electrophile
response element (ARE/EpRE) sequences in the pro-
moter regions of Nrf2 target genes. Finally, the C ter-
minus Neh3 is another transactivation domain that
recruits chromo-ATPase/helicase DNA-binding protein
6 (CHD6).
Nrf2 levels are regulated primarily by ubiquitination
and proteasomal degradation (Fig. 2). After binding to
the Neh2 domain, Keap1 mediates the Cullin3 (Cul3)/
Rbx1-dependent ubiquitination of Nrf2 [2–4]. Addi-
tionally, the Neh6 domain contains a phosphodegron
for b-TrCP/Cullin1-mediated ubiquitination [5,6].
Synoviolin (Hrd1) and WDR23-DDB1-Cul4 are two
other ubiquitin ligases that have been shown to partici-
pate in the proteasomal degradation of Nrf2 [7,8].
At homeostatic conditions, Nrf2 is a short-lived pro-
tein. Under stress conditions, Nrf2 is stabilized and
translocates to the nucleus, where it binds (as a hetero-
dimer with a member of the small Maf family of tran-
scription factors) to the ARE/EpRE sequences in the
promoter of its target genes, and activates their tran-
scription. Nrf2 targets include genes that encode
detoxification, antioxidant, and anti-inflammatory pro-
teins as well as proteins involved in the regulation of
autophagy and clearance of damaged proteins, such as
proteasomal subunits [9–11]. Activation of Nrf2 leads
to the upregulation of proteins involved in the synthe-
sis of glutathione, the main intracellular small mole-
cule antioxidant [12,13], and NADPH, which provides
reducing equivalents for the regeneration of reduced
glutathione (GSH) from its oxidized form, GSSG [14–
17]. Nrf2 also participates in the maintenance of
mitochondrial function [18,19] and quality control,
through activation of mitophagy [20,21]. Nrf2 inhibits
the transcription of genes encoding proinflammatory
cytokines and suppresses proinflammatory responses
following exposure to ultraviolet radiation [22] or
lipopolysaccharide (LPS) [23]. Such comprehensive
cytoprotective functions suggest potential benefits of
therapeutic targeting of Nrf2 to counteract neurode-
generation.
Nrf2 in neurodegenerative diseases
Aging is the primary risk factor for developing neu-
rodegenerative diseases [24]. The prevalence of age-
dependent neurodegenerative disorders, such as Alz-
heimer’s disease (AD) and Parkinson’s disease (PD),
is projected to increase due to population aging [25],
with a corresponding increase in the associated
socioeconomic impact. Genetic and environmental
risk factors also contribute to the development of
neurodegenerative diseases. Currently, there is no dis-
ease-modifying therapy for any neurodegenerative dis-
ease; and even in conditions where symptomatic
treatments are available, the therapeutic benefit is
limited. Although the clinical manifestations and
genetic causes of neurodegenerative diseases are dis-
tinct, several of these disorders share strikingly simi-
lar pathological mechanisms, including mitochondrial
impairment, excessive levels of reactive oxygen species
(ROS), neuroinflammation, and disturbances in pro-
tein homeostasis (proteostasis) [24]. Additionally,
there is an age-associated increase in oxidative dam-
age to the brain, leading to mitochondrial dysfunc-
tion, dopamine auto-oxidation, a-synuclein
aggregation, glial cell activation, alterations in cal-
cium signaling, and excess free iron [26]. Dopaminer-
gic neurons show linear decline of 5–10% per decade
with aging, and this process is accelerated in PD
patients. A meta-analysis of PD and AD microarray
datasets identified 31 common downregulated genes
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Fig. 1. Domain structure of Nrf2. The low affinity binding ‘DLG’ motif and the high affinity binding ‘ETGE’ motif in the N-terminal Neh2
domain, through which Nrf2 binds to Keap1, are indicated. Also shown is the phosphodegron in the Neh6 domain through which, following
phosphorylation by glycogen synthase kinase 3 (GSK3), Nrf2 binds to b-transducin repeat-containing protein (b-TrCP).
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containing the ARE/EpRE consensus sequence in
their promoters, in addition to increased levels of
Nrf2 [27]. Increased oxidative stress was observed in
human peripheral blood mononuclear cells isolated
from individuals with mild cognitive impairment and
from 3-month-old 3xTg-AD male mice, which was
due to increased levels of nuclear Nrf2 and reduced
superoxide dismutase 1 (SOD1) mRNA in the brain
cortex [28]. The AT-Nrf2-knockout mouse model,
that combines amyloidopathy and tauopathy with
Nrf2 deficiency, presents increased markers of oxida-
tive stress and neuroinflammation in the brain tissue
compared to AT-Nrf2-wild-type mice [29]. Further-
more, young adult AT-Nrf2-knockout mice have defi-
cits in spatial learning and memory and reduced
long-term potentiation in the perforant pathway.
Transcriptomic analysis has shown that Nrf2-knock-
out mouse brains share 7 and 10 of the most
dysregulated pathways with aging human and AD
brains, respectively [29].
Oxidative stress in neurodegenerative
disease and the counteracting role of
Nrf2
The brain is especially sensitive to changes in cellular
redox status; therefore, maintaining redox homeostasis
in the brain is critical for preventing oxidative stress-
induced cellular damage [24,25]. Nrf2 regulates the
expression of a variety of antioxidant enzymes and
proteins that exert cytoprotective effects, and there is
mounting evidence demonstrating improvement of
neurological phenotypes in disease models following
the induction of Nrf2-dependent antioxidant activities.
Synaptic degeneration and neuronal death that char-
acterize AD are caused by several deregulated
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Fig. 2. Regulation of Nrf2 by ubiquitination
and proteasomal degradation. Four known
ubiquitin ligase systems mediate the
degradation of Nrf2: Keap1, a substrate
adaptor protein for Cul3/Rbx1-based
ubiquitin ligase and a cysteine-based sensor
for Nrf2 inducers; b-TrCP, a substrate
adaptor for Skp1-Cul1/Rbx1-based ubiquitin
ligase, WDR23-DDB1-Cul4//Roc1-based
ubiquitin ligase, and Hrd1. Keap1-mediated
degradation requires that its cysteine
sensors are in reduced state. b-TrCP-
mediated degradation requires formation of
a phosphodegron catalyzed by glycogen
synthase kinase 3 (GSK3), which in turn
requires phosphorylation by a priming
kinase. Hrd1-mediated degradation of Nrf2
occurs during ER stress.
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processes including: (a) increased oxidative stress, (b)
chronic inflammation (c) mitochondrial dysfunction,
(d) accumulation of amyloid-b (Ab) 1–42 peptides,
generated from the amyloid precursor protein (APP),
(e) proteasome inhibition, (f) mutations in APP,
presenilin-1 and presenilin-2 genes, and (g) aggregation
of hyper-phosphorylated tau protein [30]. Oxidative
stress is, at least partially, induced by oligomeric Ab
peptides, and precedes other biochemical changes,
while oxidative damage in turn induces chronic
inflammation.
Carnosic acid (Fig. 3) is a natural pro-electrophilic
compound that is converted to its active form by
oxidative stress, which in turn activates Nrf2-dependent
transcription [31]. In vitro, carnosic acid reduced den-
dritic spine loss in rat neurons exposed to neurotoxic
oligomeric Ab. In vivo, carnosic acid treatment of
human amyloid precursor protein (hAPP)-J20 mice
improved learning and memory. Histological analysis
showed that carnosic acid increased dendritic and
synaptic markers, and decreased astrogliosis, Ab
plaque number, and phospho-tau staining in the hip-
pocampus. Sulfuretin (Fig. 3), a flavonoid glycoside,
significantly attenuated the decrease in cell viability
and accumulation of ROS associated with Ab25-35-
induced neurotoxicity in neuronal cells [32]. Sulfuretin
stimulated the activation of Nrf2, resulting in
increased expression of the antioxidant Nrf2-target
gene heme oxygenase-1 (HO-1). The neuroprotective
effects of sulfuretin were diminished following Nrf2
small interfering RNA (siRNA) injection and the addi-
tion of HO-1 inhibitor zinc protoporphyrin IX [32].
Parkinson’s disease is characterized by progressive
loss of dopaminergic neurons and profound reduction
of dopamine in the striatum. Although multiple
genetic and environmental factors have been impli-
cated in the etiology of PD, the majority of the clinical
cases are sporadic. The 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine (MPTP) mouse model of PD reca-
pitulates the effects of the neurotoxin MPTP-induced
Parkinsonism in humans. Nrf2 activation showed neu-
roprotective effects in MPTP mice, and these were
associated with a reduction of oxidative damage and
neuroinflammation [33–36]. Notably, astrocytes from
adult and old rats are more susceptible to MPP+ toxic-
ity than astrocytes from newborn rats, but following
pretreatment with the Nrf2 activator tert-butyl-hydro-
quinone (Fig. 3), Nrf2-dependent expression of antiox-
idant enzymes is increased, resulting in cytoprotection
[37].
Huntington’s disease (HD) is an autosomal domi-
nant and highly penetrant neurodegenerative disorder,
which results from the pathological expansion of
trinucleotide CAG repeats – encoding polyglutamine –
in the huntingtin (HTT) protein [38]. At the time of
diagnosis, brains from HD patients show marked stri-
atal and cortical atrophy. Although the pathogenesis
of HD is complex, oxidative stress is an important dri-
ver of pathology. Compared to nondisease controls,
the levels of Nrf2 targets, including glutathione peroxi-
dase, catalase, and SOD1, are increased in human HD
brains [39]. This suggests a partial activation of the
Nrf2-dependent antioxidant defense. Based on studies
using various animal models, pharmacological Nrf2
activation holds promise for combating oxidative stress
in HD.
Role of Nrf2 in mitochondrial function
Nrf2 regulates cellular defense through the modulation
of mitochondrial function. Nrf2 induction counterbal-
ances mitochondrial production of ROS and defends
against mitochondria-produced toxins [19,40]. Nrf2
function is decreased in mitochondria-related disor-
ders, such as AD, PD, and Friedreich’s ataxia
(FRDA). Studies using isolated mitochondria and cul-
tured cells have demonstrated that Nrf2 deficiency
leads to impaired mitochondrial fatty acid oxidation,
respiration, and ATP production [18,41]. Chemical
activators of Nrf2 promote mitochondrial integrity
either by inducing mitophagy [20,21] or by conferring
resistance to the oxidative stress-mediated opening of
the mitochondrial permeability transition pore [42,43].
Emerging evidence suggests that Nrf2 also influences
mitochondrial biogenesis, particularly under stress
conditions. Nrf2 activates proliferator-activated recep-
tor gamma coactivator 1a (PGC-1a) and nuclear respi-
ratory factor 1, thereby stimulating mitochondrial
biogenesis [44]. A recent report has shown that
increased proteasomal activity, one of the conse-
quences of Nrf2 activation, leads to enhanced degrada-
tion of the mitochondrial fission protein dynamin-
related protein 1 (Drp1), promoting mitochondrial
hyperfusion [45]. The lower levels of Drp1 under con-
ditions of Nrf2 activation could be beneficial in AD as
partial reduction of Drp1 decreases the levels of phos-
phorylated Tau, a major microtubule-associated pro-
tein (MAPT) of mature neurons, and improves
mitochondrial dynamics and synaptic activity in Tau
transgenic (P301L) mice [46].
Mitochondrial mass and oxygen consumption
increase in primary glial cultures following treatment
with the a7 acetylcholine nicotinic receptor (nAChR)
agonist PNU282987 in the absence of oxidative stress
[47]. Importantly, these changes were abolished when
either Nrf2 was absent, HO-1 was inhibited, or PGC-
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1a was silenced. Moreover, microglia of PNU282987-
treated animals showed a significant increase in mito-
chondrial content, while in HO-1 mutant (LysMcre-
Hmox1D/D) and PGC-1a-deficient strains, the animals
showed lower mitochondrial levels in microglia and
treatment with PNU282987 was ineffective. These
results suggest that a7 nAChR signaling increases glial
mitochondrial mass via Nrf2-dependent stimulation of
HO-1 and PCG-1a.
Transcriptomic and metabolomic analyses of mutant
Drosophila deficient for the mitochondrial serine/thre-
onine-protein kinase PTEN-induced putative kinase 1
(PINK1), a model of PD, showed that PINK1 defi-
ciency leads to alterations in nucleotide metabolism,
suggesting that enhancing nucleotide biosynthetic
pathways could be a strategy to reverse mitochondrial
dysfunction in PD [48]. Activation of Nrf2 increases
the glucose flux through the pentose phosphate
pathway and affects the metabolism of folate and glu-
tamine, which in addition to upregulating NADPH
and GSH biosynthesis (mentioned above), results in
enhanced purine biosynthesis [17]. Thus, enhancing
nucleotide biosynthesis via Nrf2 activation might
reverse mitochondrial dysfunction in PINK1 defi-
ciency. This idea is supported by experiments showing
that pharmacological activation of Nrf2 in PINK1-
knockout cells restores the mitochondrial membrane
potential (Δwm) and protects against dopamine toxicity
[49].
Friedreich’s ataxia is an autosomal recessive neu-
rodegenerative disorder, caused by the expansion of
intronic GAA repeats resulting in reduced levels of the
mitochondrial protein frataxin – an essential protein
for the biogenesis of iron-sulfur clusters and proper
functioning of mitochondrial respiratory chain com-
plexes [50]. Several studies using mouse models and
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cultured cells from patients with FRDA, have reported
impaired Nrf2 signaling in FRDA [50–52]. The sensi-
tivity to oxidative stress of YG8R and KIKO fibrob-
lasts from FRDA mouse models can be prevented by
Nrf2 inducers, such as the isothiocyanate sulforaphane
(Fig. 3) and the tricyclic cyanoenone TBE-31 (Fig. 3)
[53]. The pentacyclic cyanoenone RTA-408
(Omaveloxolone) (Fig. 3) is currently in a Phase 2 clin-
ical trial in FRDA patients (ClinicalTrials.gov). Inter-
estingly, Nrf2 binds an upstream response element in
the frataxin locus, and the anesthetic dyclonine has
been shown to activate Nrf2, increase the mRNA and
protein levels of frataxin and rescue frataxin-dependent
enzyme deficiencies in the iron-sulfur enzymes aconi-
tase and succinate dehydrogenase [54].
Role of Nrf2 in neuroinflammation
A bidirectional communication takes place between
the brain and the peripheral immune system in both
physiological and pathological conditions [55]. Brain
inflammation results from acute injury or following
the accumulation of mutant proteins or endogenous
neurotoxic metabolites such as those associated with
neurodegenerative diseases, including AD and PD.
Microglia, in particular, play a key role in brain
inflammation via the release of proinflammatory cyto-
kines. Increased neuroinflammation and oxidative
stress following microglial activation are associated
with age-related cognitive impairment [55,56].
The anti-inflammatory properties of Nrf2 signaling
are well established, and recent evidence suggests a
mechanism of transcriptional repression of proinflam-
matory cytokines (TNF-a, IL-1, IL-6, IL-8, MCP-1) in
microglia, macrophages, monocytes, and astrocytes
following Nrf2 activation [23,57]. The Nrf2 activator
sulforaphane increased Nrf2 DNA-binding activity
and upregulated Nrf2 target genes in RAW264.7 cells,
BV2 microglia cells and primary mouse microglia,
while reducing LPS-induced interleukin IL-1b, IL-6,
and inducible nitric oxide synthase (iNOS) [58–60].
Furthermore, representatives of seven distinct chemical
classes of Nrf2 activators show highly correlated
upregulation of NQO1 – a prototypic Nrf2 target –
and suppression of iNOS and COX-2 expression in cell
lines and primary mouse peritoneal macrophages
[61,62].
Oral administration of the kavalactone methysticin
(Fig. 3) activated the Nrf2 pathway in the hippocam-
pus and cortex of AD (APP/Psen1) mice [63]. This
treatment reduced microgliosis, astrogliosis, and the
secretion of the proinflammatory cytokines TNF-a
and IL-17A, as well as oxidative damage. Most
importantly, the long-term memory decline of AD
mice was significantly attenuated.
Several human studies have demonstrated the pro-
tective effects of n-3 polyunsaturated fatty acids (n-3
PUFA), particularly in the early stages of mild cogni-
tive impairment preceding AD [64]. The Nrf2-depen-
dent anti-inflammatory and antioxidant effects of n-3
PUFA have been linked to a lower activation of
microglia. It has been suggested that n-3 PUFA shift
microglia from the macrophage M1 to an M2 pheno-
type, resulting in lower oxidative stress and enhanced
phagocytic activity toward Ab peptide [64].
Nrf2 signaling-mediated oxidative stress and neu-
roinflammation have also been implicated as the key
therapeutic targets for amyotrophic lateral sclerosis
(ALS). Genetic studies in ALS mouse models have
shown a significant therapeutic effect of elevated Nrf2
levels in astrocytes, the major GSH suppliers for
neighboring neurons [65]. Moreover, Nrf2 signaling is
critical for attenuating neuroinflammation in ALS
through repression of the deleterious effects of acti-
vated microglia on neuronal survival. Consistent with
the therapeutic potential of Nrf2 signaling, treatment
with small molecule activators, including the potent
cyanoenone triterpenoids, has shown efficacy in mouse
models of ALS [66].
Role of Nrf2 in autophagy
Autophagy recycles macromolecular aggregates, result-
ing from oxidative stress, and may also reduce the
mitochondrial production of ROS through recycling of
old and damaged mitochondria [67,68]. The deregula-
tion of autophagy initiation or progression results in
the accumulation of aggregation-prone proteins in neu-
ronal and extraneural tissues.
Nrf2 promotes autophagy via induction of the
autophagosome cargo protein p62/sequestosome-1
(p62/SQSTM1) [69,70] and other autophagy-related
genes [10]. Knockdown of Nrf2 reduces autophagic
flux, whereas pharmacological Nrf2 activation pro-
motes autophagy, and this closely correlates with
changes in the levels of p62/SQSTM1 [69,70]. This
area of research is of particular importance given the
strong association between neurological phenotypes
and the presence of accumulated misfolded proteins in
affected brains, and deficiency of the protein degrada-
tion machinery in neurodegenerative diseases. The role
of Nrf2 in the clearance of misfolded proteins has
received much attention in recent studies, and the rela-
tionship with other Nrf2-controlled stress responses
has been evaluated in neurodegenerative and healthy
conditions.
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Redox mechanisms of autophagy regulation have
been documented at the level of crosstalk between the
Nrf2 pathway and p62-associated autophagy. In a
Drosophila model of FRDA, genetic or pharmacologic
inhibition of the mechanistic target of rapamycin com-
plex 1 (TORC1) signaling led to an increase in the cel-
lular levels of ATP and organismal lifespan, which was
in part due to enhanced transcription of antioxidant
genes mediated by the Drosophila ortholog of Nrf2
[71]. Notably, under condition of oxidative stress, the
protective effect of TORC1 inhibition was abolished
upon inhibition of autophagy.
A recent study has demonstrated that nine autop-
hagy genes containing ARE/EpRE sequence are
responsive to Nrf2 activation by sulforaphane in
human and mouse cells [10]. Mouse embryonic fibrob-
lasts from Nrf2-knockout mice have reduced expres-
sion of autophagy genes, and this deficiency can be
rescued by an Nrf2-expressing lentivirus [10]. Com-
pared to their wild-type counterparts, the neuronal
levels of p62/SQSTM1, CALCOCO2/NDP52, ULK1,
ATG5, and GABARAPL1 are low in Nrf2-deficient
mice co-expressing mutant APP (HsAPPV717I) and
MAPT (HsMAPTP301L), and these animals have
more intracellular aggregates of the mutant proteins.
Additionally, in the absence of Nrf2, the colocalization
of the mutant APP and MAPT proteins with p62/
SQSTM1 was impaired. The same study showed that
in AD patient samples, neurons expressing high levels
of APP or MAPT also have high levels of nuclear
Nrf2 and its transcriptional target p62/SQSTM1 [10].
A hallmark of the AD brain is the presence of senile
plaques containing insoluble amyloid-b peptide, a
cleavage product of the APP, which is physiologically
degraded by autophagy. The neurotoxic amyloid-b
peptide is the result of the enzymatic activity of b and/
or c secretase. The effect of genetic removal of Nrf2
has been investigated in double transgenic mice
expressing a chimeric mouse/hAPP (Mo/
HuAPP695swe) and a mutant human c secretases (pre-
senilin 1 (PS1-dE9) [72]. Compared to Nrf2-proficient
animals, APP/PS1 mice that are also deficient for Nrf2
had higher intracellular levels of APP, Ab (1–42), and
Ab (1–40), which was accompanied by enhanced
inflammation. In these Nrf2 mutant mice, the levels of
poly-ubiquitin-conjugated proteins were increased,
APP and Ab were primarily found in the insoluble
fraction, and autophagy was impaired – as evidenced
by accumulation of multivesicular bodies, endosomes,
and lysosomes.
In certain cases of PD, rare mutations in leucine-rich
repeat kinase 2 (LRRK2) and a-synuclein (a-Syn) lead
to neurodegeneration, associated with accumulation of
misfolded proteins [73,74]. Using a longitudinal imag-
ing platform, the fate and location of mutant LRRK2
and a-Syn were recently investigated in single live neu-
rons [75]. Activation of Nrf2 protected against the tox-
icity of the mutant proteins in a cell-autonomous and
time-dependent manner. Interestingly, the protective
effect of Nrf2 was different depending on the mutant
proteins: Nrf2 activation led to a decrease in the
steady-state levels of a-Syn by increasing its degrada-
tion, whereas misfolded diffuse LRRK2 was seques-
tered into inclusion bodies [75].
Genetic studies have identified rare mutations in
SQSTM1 gene, which causes susceptibility to fron-
totemporal lobar degeneration (FTLD) and ALS,
which further emphasizes a relationship between Nrf2
and autophagy. The term FTLD describes a spectrum
of neurodegenerative disorders, characterized, by the
deposition of misfolded proteins and focal atrophy of
frontal and/or temporal lobes [76]. Mutations in genes
encoding three autophagy adaptor proteins, p62/
SQSTM1, ubiquilin 2, and optineurin, represent a
known causative factor for FTLD, implicating autop-
hagy in FTLD pathogenesis. In the majority of FTLD
cases, the accumulated protein aggregates contain
either microtubule-associated protein tau or TAR
DNA-binding protein (TDP)-43 [77]. Intracellular
deposition of TDP-43 is characterized by prominent
neuronal granular cytoplasmic immunoreactivity and
abundant oligodendroglial inclusions [78]. Aggregates
are also positive for ubiquitin and p62/SQSTM1, indi-
cating that these aggregates are targeted for degrada-
tion [79]. During autophagy, the recognition of the
lipidated form of microtubule-associated protein light
chain 3 isoform B (LC3B-II) within the phagophore
membrane by p62/SQSTM1 represents a critical pro-
tein–protein interaction that is mediated through its
LC3-interacting region, and notably, some FTLD and
ALS mutations of p62/SQSTM1 map to this region,
leading to reduction in LC3B binding affinity and lim-
iting the recruitment of p62/SQSTM1 to the phago-
phore [80].
Mutations in SQSTM1 have been found in patients
with ALS, FTLD or with FTLD/ALS when both syn-
dromes are present in the same person [81]. Analysis
of 348 ALS and FTLD missense mutations in 14 genes
focusing on protein stability based on available 3D
structures predicted that most of the missense muta-
tions with destabilizing energies occur in the regions
that control protein–protein interactions, and that the
predicted destabilization is greater for ALS compared
to FTLD mutations and correlates with disease pro-
gression. However, other ALS causative mutations,
which span throughout the SQSTM1 gene, have been
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identified, namely E81K, N239K, G297S, E372D,
P388S, and P392L, suggesting more complex functions
of the protein in disease pathogenesis [82]. Intrigu-
ingly, some SQSTM1 mutations are associated with
reduced Nrf2 activation in FTLD/ALS [83], with phar-
macological Nrf2 activators showing beneficial effects
[84].
Nrf2 signaling in aging
Although some of the downstream biochemical path-
ways regulated by Nrf2 are directly implicated in neu-
rodegeneration, it is important to evaluate the role of
Nrf2 and its impact on the aging processes in the brain
as a conceptual paradigm. Aging is tightly associated
with redox events, and the free radical theory of aging
indicates that redox imbalance may be a promoting
factor. A study using Caenorhabditis elegans and
human fibroblasts compared differential responses to
oxidative stress challenge in young and old individuals
[85]. In young individuals, higher levels of ROS were
generated, and signaling pathways, including p-ERK,
p-AKT, and p-AMPKa/b, were activated in response
to oxidative stress. Nrf2 translocated to the nucleus
and induced the expression of antioxidant and detoxifi-
cation enzymes, including SOD1, CAT, GPX, HO-1,
GSTP-1, to maintain redox homeostasis. Moreover,
young individuals had a better capacity to degrade
damaged proteins by upregulating the expression of
molecular chaperones and enhancing the activity of
the proteasome [85].
Compelling evidence for Nrf2 suppression in aging
came from a study of Hutchinson-Gilford progeria
syndrome (HGPS), a rare fatal premature aging disor-
der [86]. The cause for the disease is progerin, a
mutant form of the nuclear architectural protein lamin
A. The constitutive production of progerin leads to
morphological, genomic, and epigenetic changes, and
to mesenchymal stem cell attrition. The study found
that progerin sequesters Nrf2, resulting in subnuclear
mislocalization and impaired activity of Nrf2 leading
to chronic oxidative stress. The aging defects that
occur in HGPS fibroblasts can be recapitulated by
Nrf2 knockdown or increased oxidative stress caused
by treatment with hydrogen peroxide of wild-type
fibroblasts. Conversely, activation of Nrf2 by genetic
or pharmacological (by oltipraz treatment) means
reverses the nuclear aging defects in HGPS patient
cells and restores the viability of HGPS mesenchymal
stem cells implanted into the tibialis anterior muscle of
immunodeficient mice. These findings strongly suggest
that repression of Nrf2 signaling is an essential con-
tributor to the premature aging phenotype.
The regenerative function of neural stem/progenitor
cells (NSPCs) continuously declines with advancing
age. This specific temporal pattern of NSPC decline is
functionally relevant at a behavioral level and corre-
lates with decreased levels of Nrf2 [87]. Moreover,
newborn Nrf2-knockout mice exhibit a lower number
of NSPCs in comparison with their wild-type counter-
parts, and the proliferative and neurogenic potential of
these NSPCs is compromised in these Nrf2-deficient
animals.
The age-dependent decline in stem cell proliferation
is most likely due to dysregulated signaling in the neu-
rogenic niche and increased levels of inflammatory
cytokines [88]. Treatment with NT-020, a proprietary
blend of polyphenols, led to an increase in nuclear
localization of Nrf2 and expression of its downstream
transcriptional target HO-1 in all subsets of cell types
in the subgranular zone of the dentate gyrus and the
subventricular zone in brains of both young and aged
rats. Analyses of hippocampal tissue showed that the
levels of a number of proinflammatory factors, includ-
ing TNF-a and IL-1b, were reduced, whereas the levels
of the anti-inflammatory cytokines IL-24, IL-4, and
IL-10 increased. Furthermore, NT-020 treatment
improved performance on a spatial learning task in
aged rats [89].
An important question is which aging brain cells
lose their Nrf2 activation responses? Markers of Nrf2
activity can be observed in neurons in postmortem
brain tissue and animal models of disease; however,
recent evidence demonstrates that Nrf2 activity is low
in iPS-derived human neurons [90], and that during
mouse cortical neuronal development in vitro and
in vivo, the expression of Nrf2 is repressed by epige-
netic inactivation of its promoter [91]. In contrast,
non-neuronal cells such as astrocytes demonstrate con-
sistent in vitro and in vivo Nrf2 activation responses
[92]. Astrocytes are highly dynamic cells that have
roles in the maintenance of brain homeostasis and
energy metabolism, regulation of neurotransmission,
and processing of synaptic information and inflamma-
tory triggers [93]. One essential function of astrocytes
is to provide antioxidant support to neighboring neu-
rons [94]. Consistently with their critical role, an astro-
cyte-specific, but not neuronal-specific, Nrf2-activation
rescued the neurological phenotype of mutant SOD1
mouse model of ALS [95]. Astrocytes show an age-
dependent increase in oxidative/nitrosative stress, mito-
chondrial dysfunction, RNA oxidation, NADPH oxi-
dase activity, superoxide levels, and iNOS expression.
Astrocytes also display age-dependent inflammatory
response with higher levels of proinflammatory cytoki-
nes, such as TNF-a, IL-1b, IL-6, IL-18, as well as
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increased mRNA levels of cyclooxygenase 2 (COX-2)
[93]. Nevertheless, aged astrocytes are amenable for
Nrf2 activation and represent a target cell type for
therapeutic intervention [37].
Long-term consumption of high fat diet (HFD) con-
tributes to cognitive impairment in aged mice [96]. A
16-week HFD increased age-related oxidative damage
(protein carbonyls) in the brain and impaired cognitive
performance in behavioral tests of 20-month-old male
mice. This selective increase in oxidative damage and
cognitive decline was associated with decreased levels
and activity of Nrf2, suggesting the involvement of
lower antioxidant responses. In contrast to HFD con-
sumption, moderate caloric restriction (CR) confers
antioxidative and anti-inflammatory effects, preserving
a youthful phenotype in rodents [97]. CR prevents
age-related increases in oxidative stress and inflamma-
tion and age-related dysfunction of Nrf2. Intriguingly,
exposure of aged cells to resveratrol, a CR mimicking
compound and an activator of the cellular energy sen-
sor AMP-activated protein kinase (AMPK) [98],
results in rapid activation of Nrf2 signaling [99], con-
sistent with early reports on the ability of this com-
pound to induce drug metabolizing enzymes and
inhibit inflammation [100]. Oral administration of
another natural product, thymol (Fig. 3), a monoter-
pene phenol, has been shown to exhibit neuroprotec-
tive effects in C57BL/6J mice fed a HFD for 12 weeks
[101]. Thymol treatment significantly reversed the gain
of body weight, improved cognitive impairments and
decreased HFD-induced Ab deposition and tau hyper-
phosphorylation in the hippocampus, and these protec-
tive effects of thymol were associated with activation
of Nrf2 signaling.
Chronic administration of testosterone propionate
to aged rats has been shown to ameliorate the decline
of balancing reactions and muscular strength associ-
ated with aging [102]. Interestingly, these beneficial
effects are also correlated with decreased oxidative
stress, increased protein levels of Nrf2 and its tran-
scriptional targets HO-1 and NQO1, and greater num-
ber of tyrosine hydroxylase immunoreactive cells in
substantia nigra, implicating Nrf2 as an important
mediator of some of the physiological and behavioral
effects of testosterone.
Nrf2-dependent amelioration of age-
dependent neurological phenotype
A number of pharmacological Nrf2 activators are cur-
rently in clinical trials, and the fumaric acid ester
dimethylfumarate (Fig. 3) is an FDA-approved drug
(Tecfidera, Biogen-Idec) for the treatment of relapsing
multiple sclerosis (MS). Dimethylfumarate blocks the
degradation of Nrf2 by covalent modification of cys-
teine 151 in Keap1 [103], which in addition to serving
as a substrate adaptor for Cul3-mediated degradation
for Nrf2, acts as the protein sensor for electrophilies
and oxidants [104]. Following stereotaxic delivery of
recombinant adeno-associated viral vector expressing
human a-synuclein to the ventral midbrain of mice,
daily oral administration of dimethylfumarate pro-
tected nigral dopaminergic neurons against the toxicity
of a-synuclein, and decreased astrocytosis and
microgliosis; notably, this protective effect was not
observed in Nrf2-knockout mice [105]. Dimethylfu-
marate is, however, of a relatively low potency and
specificity. Other molecules with similar mechanism of
action or with the ability to directly disrupt the
Keap1/Nrf2 interaction are emerging as potential pro-
tective agents for the prevention and treatment of a
broad range of currently incurable neurodegenerative
diseases [57,59,106]. Inhibition of Keap1 has also been
shown to prevent neuronal toxicity in response to the
AD-initiating Ab42 peptide, in correlation with Nrf2
activation [106]. Consistent with this notion, pharma-
cological activation of Nrf2 by the cyanoenone triter-
penoids CDDO-ethyl amide and CDDO-trifluoroethyl
amide (Fig. 3) induces broad antioxidant effects in
HD mouse brain and ameliorates the neurological phe-
notype [107]. The benefits of Nrf2 activation can be
extended to other polyglutamine diseases such as
spinal and bulbar muscular atrophy (SBMA, also
known as Kennedy’s disease) [108].
Concluding remarks
In summary, it is becoming increasingly clear that
Nrf2 activation counteracts multiple pathogenic pro-
cesses involved in neurodegenerative disorders through
upregulation of antioxidant defenses, inhibition of
inflammation, improvement of mitochondrial function,
and maintenance of protein homeostasis (Fig. 4).
Finally, it is worthwhile pointing out that there
appears to be a notable inverse relationship between
the expression of mutant proteins that are causally
associated with a number of neurodegenerative dis-
eases and Nrf2-dependent cytoprotective responses.
Increased nuclear translocation of Nrf2 is found in a
mutant transactive response DNA-binding protein 43
(TDP-43) transgenic model of ALS, but the expression
of downstream antioxidant enzymes is decreased [109].
A gene expression profiling has revealed an upregula-
tion of Nrf2-target gene expression in the spinal cord
of TDP-43Q331K mice compared to their control
counterparts; however, the corresponding protein
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levels were not increased [110]. In TDP-43M337V
patient fibroblasts and astrocyte cell cultures from
TDP-43Q331K mice, the levels of glutathione are low
even though the mRNA levels of antioxidant enzymes
are high [110]. An increase of nuclear Nrf2 in brain
cortex, but a decreased expression of Nrf2-responsive
targets was reported in an AD mouse model [28]. The
activation of Nrf2 by proteasomal inhibition is inhib-
ited in cells expressing PINK1 G309D [111], a mutant
PINK1 causally associated with hereditary early-onset
PD [112]. The repressive effects of mutant HTT on
Nrf2 responses have been observed in immortalized
murine striatal cells expressing mutant HTT [113] and
in human HD neural stem cells [57]. Importantly,
pharmacological Nrf2 activation, which was essentially
absent in HD neural stem cells with an extreme (72)
CAG repeat length, was restored upon isogenic genetic
correction of the CAG expansion to a nonpathological
(21) CAG repeat length [57]. Collectively, these find-
ings suggest a negative effect of a number of mutant
proteins across a large spectrum of neurodegenerative
diseases on functional Nrf2-dependent responses and
thus a possible exacerbation of the neurological
phenotype through reduced Nrf2 signaling. Nonethe-
less, there is a growing body of convincing experimen-
tal evidence demonstrating that pharmacological Nrf2
activation is beneficial in counteracting many of the
pathological processes that occur in neurodegenerative
diseases, which although of distinct clinical manifesta-
tions, share similar molecular mechanisms. Thus, tar-
geting Nrf2 signaling by pharmacological entities,
some of which are currently in clinical trials, may
provide a therapeutic option to delay onset, slow
progression, and ameliorate symptoms of neurodegen-
erative disorders, including clinical cases of unknown
etiology.
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